Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$41.18 USD

41.18
3,306,805

+0.86 (2.13%)

Updated Aug 13, 2024 04:00 PM ET

After-Market: $41.19 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pfizer's (PFE) RSV Vaccine for Infants Gets FDA Panel Vote

by Zacks Equity Research

The FDA's decision on Pfizer's (PFE) BLA seeking approval for its RSV vaccine candidate in infants through maternal immunization is expected in August.

Neena Mishra headshot

Biotech ETFs Pop on M&A Resurgence

by Neena Mishra

2023 could be a year of heightened biotech dealmaking activity

Ionis (IONS) Q1 Earnings Surpass Estimates, Sales Match

by Zacks Equity Research

Ionis (IONS) reports a narrower-than-expected Q1 loss. Sales come in line with estimates. The company re-affirms its previously issued financial guidance for 2023.

Is WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DNL

Are Medical Stocks Lagging BioRad Laboratories (BIO) This Year?

by Zacks Equity Research

Here is how Bio-Rad Laboratories (BIO) and GSK (GSK) have performed compared to their sector so far this year.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Gilead's (GILD) Q1 Earnings Miss, Veklury Sales Plunge

by Zacks Equity Research

Gilead's (GILD) Q1 earnings and sales miss estimates due to lower Veklury sales.

GSK or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GSK vs. TECH: Which Stock Is the Better Value Option?

Stock Market News for Apr 27, 2023

by Zacks Equity Research

Wall Street closed mixed on Wednesday.

GSK Beats on Q1 Earnings, Lags Sales, Reaffirms 2023 Outlook

by Zacks Equity Research

Though GSK's revenues benefit from strong growth across all segments, the declining COVID-19 antibody sales do not bode well. Management reaffirms its 2023 guidance.

GSK (GSK) Tops Q1 Earnings Estimates

by Zacks Equity Research

Glaxo (GSK) delivered earnings and revenue surprises of 5.88% and 1.28%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

GSK (GSK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

GSK (GSK) closed the most recent trading day at $36.91, moving +0.71% from the previous trading session.

Mark Vickery headshot

Top Stock Reports for Linde, Vertex Pharmaceuticals & Edwards Lifesciences

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Linde plc (LIN), Vertex Pharmaceuticals Incorporated (VRTX) and Edwards Lifesciences Corporation (EW).

GSK Gears Up to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

We expect GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Bexsero, Shingrix and Juluca to drive first-quarter sales.

GSK (GSK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, GSK (GSK) closed at $36.93, marking a +0.41% move from the previous day.

Biotech Stock Roundup: MDGL, PCVX Up on Study Data, MRNA Provides Updates

by Zacks Equity Research

Pipelines updates from Madrigal (MDGL) and Vaxcyte, (PCVX) are the key highlights of the biotech sector.

Bellus Health (BLU) Stock Up 99% on $2B Buyout Offer From GSK

by Zacks Equity Research

Bellus Health (BLU) gets an offer to be acquired by pharma bigwig, GSK for an approximate total equity value of $2 billion. The stock is up 99%, following the news.

GSK (GSK) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

GSK (GSK) closed the most recent trading day at $38.32, moving +1.62% from the previous trading session.

Adaptimmune (ADAP) Up 7%, Gets T-Cell Programs Rights From GSK

by Zacks Equity Research

Adaptimmune Therapeutics (ADAP) enters into a transition deal with GSK to regain rights to its proprietary T-cell therapy programs. Shares of the company surges 7% following the news.

GSK (GSK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, GSK (GSK) closed at $37.87, marking a -0.34% move from the previous day.

GSK (GSK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, GSK (GSK) closed at $36.55, marking a +1.67% move from the previous day.

Scynexis (SCYX) Inks Antifungal Drug Deal With GSK

by Zacks Equity Research

Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also continue to develop ibrexafungerp for treating invasive candidiasis.

GSK's Jemperli Effective Against First-Line Endometrial Cancer

by Zacks Equity Research

A late-stage study data shows that GSK's Jemperli reduced disease progression risk or death by 72% for treating adult patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.

GSK (GSK) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

GSK (GSK) closed at $35.04 in the latest trading session, marking a +1.92% move from the prior day.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.